Deprecated: Required parameter $cat_id follows optional parameter $type in /www/wwwroot/ebimall.com/systems/hong.php on line 2088

Deprecated: Required parameter $where follows optional parameter $tree_id in /www/wwwroot/ebimall.com/systems/hlb.php on line 3505
ApexBio/Clarithromycin/10mM (in 1mL DMSO)/A4322188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

ApexBio/Clarithromycin/10mM (in 1mL DMSO)/A4322

Related Products
Molarity CalculatorDilution Calculator
ClarithromycinCYP3A inhibitor, potent

Catalog No.A4322
SizePriceStockQty
10mM (in 1mL DMSO)
$60.00
In stock
100mg
$60.00
In stock
200mg
$100.00
In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Publications citing ApexBio Products

Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.
Nature.2018 Jun 13.
Nature.2018 Jun 27.
Nature.2018 Mar 29;555(7698):673-677.
Nature.2017 Sep 7;549(7670):96-100.
Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8
Nat Nanotechnol.2017 Dec;12(12):1190-1198.
Nature Biotechnology.2017 Jun;35(6):569-576
Nat Med.2018 Sep 17.
Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.
Cell.Available online 25 October 2018.
Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.
Cell.2018 Jun 28;174(1):172-186.e21.
Cell.2018 Feb 22;172(5):1007-1021.e17.
Cell.2017 Nov 30;171(6):1284-1300.e21.
Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.
Cell.2017 Jul 13;170(2):312-323
Nat Med.2018 Jan 29.
Nat Med.2017 Nov;23(11):1342-1351.
Cell.2017 Apr 6;169(2):286-300.
Cell.2015 Aug 27;162(5):987-1002.
Cell.2015 Feb 12;160(4):729-44.
Nature Medicine.2017 Apr;23(4):493-500.
Cancer Cell.2018 May 14;33(5):905-921.e5.
Cancer Cell.2018 Apr 9;33(4):752-769.e8.
Cancer Cell.2018 Mar 12;33(3):401-416.e8.
Cancer Cell.2017 Aug 14;32(2):253-267.e5.
Nat Methods.2018 Jul;15(7):523-526.
Cell Stem Cell.2018 May 3;22(5):769-778.e4.
Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.

Related Compound Libraries

  • DiscoveryProbe™ FDA-approved Drug Library
  • DiscoveryProbe™ Bioactive Compound Library
  • DiscoveryProbe™ Anti-infection Compound Library

Quality Control

Quality Control & MSDS

View current batch:
    Purity = 99.39%
  • COA (Certificate Of Analysis)
  • HPLC(Retest)
  • NMR (Nuclear Magnetic Resonance)
  • MSDS (Material Safety Data Sheet)
  • Datasheet

Chemical structure

Clarithromycin

Clarithromycin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
C1
V1
C2
V2

calculate

Clarithromycin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
g/mol

calculate

Chemical Properties

Cas No. 81103-11-9SDF Download SDF
Synonyms N/A
Chemical Name 6-((4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-((5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
Canonical SMILES CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
Formula C38H69NO13 M.Wt 747.95
Solubility ≥31.2 mg/mL in DMSO, ≥3.24 mg/mL in EtOH with ultrasonic and warming, <2.44 mg/ml="" in="" h2o=""> Storage Store at -20°C
Physical AppearanceA solidShipping ConditionEvaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

Clarithromycin, is a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, might build the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies.

Among 28,484 medicines of clarithromycin, 2317 persons were co-presented to statins. Co-organization of CYP3A4 metabolized statins and clarithromycin was connected with a 2.11 fold expanded danger of death or hospitalization (95 % certainty interim [CI]: 1.79-2.48). This impact was clarified by age, proof of cardiovascular malady, diabetes mellitus and use of different anti-infection agents (multivariable balanced danger proportion: 1.02, 95 % CI: 0.85-1.22). The affectability examinations did not change the noteworthiness of effect.

The danger for hospitalization or passing in persons accepting clarithromycin increments with age and cardiovascular disease yet is not causally connected with statin-clarithromycine co-organization.

Reference:A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.  Lipids Health Dis. 2015 Oct 24;14:131.

新闻动态
行业前沿
技术文章
最新产品